David Scheer was involved in the founding of Achillion and currently serves as its Chairman of the Board, Chair of the Nominating and Corporate Governance Committee and member of the Compensation Committee and the Strategy and Corporate Development Committee. He is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences.
Dr. Deshpande currently serves as President and CEO of Achillion and joined the Board of Directors in May 2013. Dr. Deshpande began his tenure at Achillion in 2001 as Vice President of Chemistry and steadily assumed additional responsibilities. Prior to Achillion, Dr. Deshpande was Associate Director at Bristol-Myers Squibb.
Dr. Fisherman is Managing Director of Synthesis Capital, formerly Advent Healthcare Ventures, a life science venture capital firm, where he specialized in biotechnology and emerging pharmaceutical investments. He has served as a director of Achillion since March 2000 and currently serves on the Audit Committee and the Strategy and Corporate Development Committee.
Mr. Frashier joined Achillion’s Board of Directors in March 2008 and currently serves as Chair of the Compensation Committee and as a member of the Audit Committee. Formerly holding Chief Executive and/or Chairman roles at OSI Pharmaceuticals, Millipore Corporation, Merrimack Pharmaceuticals and eXeGenex, and currently is President of G&G Management Associates, a life sciences consulting firm.
Mr. Graves, joined Achillion’s Board of Directors in June 2012 and currently is a member of the Compensation Committee and the Strategy and Corporate Development Committee. Mr. Graves is Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc. Prior to Intarsia, he held senior management roles at Merck, Novartis and Vertex Pharmaceuticals.
Mr. Van Nostrand has served as a member of Achillion’s Board of Directors since April 2007 and is Chair of the Audit Committee and serves as a member of the Compensation Committee. Mr. Van Nostrand formerly served as the Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc, and as Chief Financial Officer of both AGI Dermatitis and OSI Pharmaceuticals, where he also served as Chief Compliance Officer.
Dr. Verwiel joined Achillion’s Board of Directors in December 2016. Prior to its acquisition in 2014 by Forest Laboratories, Dr. Verwiel served as President, Chief Executive Officer and Board member at Aptalis Pharma. Prior to Aptalis, he held international senior management positions with Merck & Co. Inc. and at Servier.
Ms. Vitullo joined Achillion’s Board of Directors in September 2010 and is currently a member of the Nominating and Corporate Governance Committee. Ms. Vitullo is a partner with Domain Associates LLC, a venture capital firm with an exclusive focus on life sciences.